Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Alkermes

Alkermes Stock Jumps Nearly 30% In 3 Months After Hefty Profits

A Relative Strength Rating upgrade for Alkermes shows improving technical performance. Will it continue?

Investors Business Daily

Alkermes Stock Gets RS Rating Upgrade; Profits Surge

Alkermes Stock Gets RS Rating Upgrade; Profits Surge

Alkermes shows rising price performance, earning an upgrade to its IBD Relative Strength Rating

Investors Business Daily

Alkermes Plummets In Huge Volume. Why One Analyst Says The Reaction Is Overdone.

Alkermes Plummets In Huge Volume. Why One Analyst Says The Reaction Is Overdone.

Alkermes stock plummeted to its lowest price since last December on disappointing test results for its experimental narcolepsy treatment.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

3 Biotech Stocks to Buy This Month and Beyond

Owing to the critical medical needs, the lookout for new technologies to deal with future advancements is at its peak. Breakthrough innovations, revolutionary treatments, and a booming industry align to make biotech stocks a potential goldmine for savvy investors. Therefore, it could be wise to invest in quality biotech stocks…

3 Value Stocks Investors Want

Strong recent economic data and still-elevated inflation are expected to keep the Fed on track for another interest rate hike next month. With the stock market likely to remain volatile amid rising interest rates and other macro uncertainties, fundamentally sound stocks Astellas (ALPMY), Alkermes (ALKS), and AstroNova (ALOT), trading at…

Alkermes Stock Sees Rising Relative Strength Rating

Alkermes shows rising price performance, earning an upgrade to its IBD Relative Strength Rating

Investors Business Daily

Alkermes Stock Sees Rising Relative Price Strength

A Relative Strength Rating upgrade for Alkermes shows improving technical performance.

Investors Business Daily

inkl

Read news from The Economist, FT, and more,
with one subscription

Why Seattle Genetics, Alkermes Are Currently Outperforming Their Peers

Why Seattle Genetics, Alkermes Are Currently Outperforming Their Peers

Seattle Genetics and Alkermes beat fourth-quarter estimates Thursday, pushing Alkermes stock into a brief breakout as SGEN stock soared.

Investors Business Daily

Benzinga's Top Ratings Upgrades, Downgrades For November 3, 2022

Benzinga's Top Ratings Upgrades, Downgrades For November 3, 2022

Benzinga's Top Ratings Upgrades, Downgrades For August 16, 2022

Benzinga's Top Ratings Upgrades, Downgrades For August 16, 2022

Change Healthcare (CHNG) Q1 Earnings & Revenues Miss Estimates

Change Healthcare (CHNG) Q1 Earnings & Revenues Miss Estimates

Change Healthcare Inc. (NASDAQ: CHNG) reported first-quarter fiscal 2023 adjusted earnings per share (ETF:EPS) of 38 cents, which missed the Zacks Consensus Estimate of 39 cents by 2.6%. The bottom line declined 7.3% on a year-over-year basis.

The Cream Of The Crop: 5 Biotechs That Outrank Most Stocks

The Cream Of The Crop: 5 Biotechs That Outrank Most Stocks

The top five biotech stocks today have several commonalities. Among them are strong ratings. Some show promising charts and are Tech Leaders.

Investors Business Daily

IBD Screen Of The Day: Global Stock Leaders Highlight These Top Stocks

IBD Screen Of The Day: Global Stock Leaders Highlight These Top Stocks

A few names from the global stock screen are worth mentioning.

Investors Business Daily

IBD Screen Of The Day: Global Leaders Highlight These Top Health Care Stocks

IBD Screen Of The Day: Global Leaders Highlight These Top Health Care Stocks

GSK announced positive results in a late-stage study on a new Covid-19 vaccine targeted to combat the omicron variant.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Global Growth Stocks To Watch On IBD's Screen Of The Day Include Two Oil Stocks

IBD's Screen Of The Day features two oil stocks near buy points. Also, this biotech with excellent earnings made the list.

Looking Into Alkermes's Return On Capital Employed

Benzinga Pro data, Alkermes (NASDAQ:ALKS) reported Q1 sales of $278.55 million. Earnings fell to a loss of $35.90 million, resulting in a 4212.6% decrease from last quarter.

Investors Business Daily

IBD Stock Of The Day Alkermes Breaks Out As Its Newest Drug Snags Big Beat

Alkermes is the IBD Stock Of The Day after strong first-quarter sales of its new bipolar treatment, Lybalvi, led Alkermes stock to break out.

Investors Business Daily

Stock Market Bounces As Microsoft, Alphabet, Other Earnings Steer Trading

Indexes came off earlier gains as trading remained volatile.

Get all your
news in one place.

100’s of premium titles.
One news app.

Recap: Alkermes Q1 Earnings

Alkermes (NASDAQ:ALKS) reported its Q1 earnings results on Wednesday, April 27, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Alkermes's Earnings Outlook

Alkermes (NASDAQ:ALKS) is set to give its latest quarterly earnings report on Wednesday, 2022-04-27. Here's what investors need to know before the announcement. Analysts estimate that Alkermes will report an earnings per share (EPS) of $0.01.

Expert Ratings for Alkermes

Alkermes (NASDAQ:ALKS) has observed the following analyst ratings within the last quarter:

5 Outperforming Biotech Stocks with More Room to Run

Thanks to the global COVID-19 vaccination drive and inelastic demand for healthcare, biotechnology stocks have been outperforming the broader markets so far this year. Because this trend will likely continue, we think investing in popular biotech stocks Regeneron Pharmaceuticals (REGN), Exelixis (EXEL), Jazz Pharmaceuticals (JAZZ), Alkermes (ALKS), and Incyte Corp.…

Benzinga's Top Ratings Upgrades, Downgrades For April 20, 2022

Alkermes Starts Arbitration Related to NanoCrystal Tech Agreements With Janssen

Alkermes plc (NASDAQ:ALKS) commenced binding arbitration proceedings regarding two license agreements with Janssen Pharmaceutica N.V., a subsidiary of Johnson & Johnson (NYSE:JNJ). Under these agreements, Janssen received access and rights to Alkermes' small particle pharmaceutical compound technology, known as NanoCrystal Technology, enabling several products. Janssen partially terminated the agreements in the U.S., effective as of…

Alkermes's Return On Capital Employed Overview

According to Benzinga Pro, during Q4, Alkermes (NASDAQ:ALKS) earned $873.00 thousand, a 103.01% increase from the preceding quarter. Alkermes also posted a total of $324.46 million in sales, a 10.31% increase since Q3.

1 2

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

US Federal Reserve

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

231,320 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play